Olacaftor

DB16262InvestigationalSmall molecule

Olacaftor is under investigation in clinical trial NCT02951182 (A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis).

Mechanism: Pharmacologically active on Cystic fibrosis transmembrane conductance regulator
Curator reviewed
Formula / weight: C₂₉H₃₄FN₃O₄S · 539.67 g/mol (avg)
Code names: VX-440

Resolves to

Compound

UNIIRZ7027HK8FCAS1897384-89-2ChEMBLCHEMBL4297649

Structure

InChIKeyNHOUNZMCSIHKHJ-FQEVSTJZSA-NSMILESCC(C)COC1=CC(F)=CC(=C1)C1=CC=C(C(=O)NS(=O)(=O)C2=CC=CC=C2)C(=N1)N1C[C@@H](C)CC1(C)C

Targets

P13569CFTR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Olacaftor, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account